Background: The Association of Public Health Laboratories (APHL) received a data request from the National Academies of Sciences, Engineering, and Medicine’s Addressing Sickle Cell Disease: A Strategic Plan and Blueprint for Action Project—specifically on information on how newborn screening (NBS) programs report screening results for sickle cell disease (SCD) and sickle cell trait (SCT) (i.e., follow-up processes).
Methods: APHL’s Newborn Screening and Genetics Program in collaboration with the National Academies SCD committee developed a short survey that would gather information and provide an understanding of what occurs in SCD and SCT NBS results reporting. APHL distributed a PDF version of the survey to six state NBS program representatives (Colorado, Connecticut, Florida, New Jersey, Tennessee, and Washington) of the APHL Hemoglobinopathy Laboratory Workgroup on September 10, 2019. Respondents were asked to review the questions and provide availability for a phone call with APHL staff to answer the survey questions verbally on September 13, 2019.
Results: All six respondents provided answers (five via telephone and one via e-mail). In accordance with APHL’s Data Access and Sharing policy, the reports and findings related to the survey will only be released in aggregate without individual identifiers.
Sickle Cell Disease (SCD) NBS Results Reporting
Sickle Cell Trait (SCT) NBS Results Reporting
Survey: Newborn Screening Results Reporting Protocols for Sickle Cell Disease and Trait Survey
APHL received a data request from the National Academies SCD committee specifically on information on how NBS programs report screening results for SCD and SCT (i.e., follow-up processes). The purpose of the survey is to gather the requested information. Your participation is vital to providing an understanding of what occurs in results reporting. In accordance with APHL’s Data Access and Sharing policy, the reports and findings related to this survey will be released only in aggregate data form without individual identifiers. Thank you for considering this opportunity to make a meaningful contribution.
Sickle Cell Disease (SCD):
Sickle Cell Trait (SCT):
This page intentionally left blank.